Review



stimulation by heregulin  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems stimulation by heregulin
    Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to <t>heregulin-β</t> <t>stimulation</t> ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.
    Stimulation By Heregulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 96 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stimulation by heregulin/product/R&D Systems
    Average 94 stars, based on 96 article reviews
    stimulation by heregulin - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network"

    Article Title: Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network

    Journal: European Journal of Pharmaceutical Sciences

    doi: 10.1016/j.ejps.2011.10.026

    Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to heregulin-β stimulation ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.
    Figure Legend Snippet: Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to heregulin-β stimulation ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.

    Techniques Used:

    Experimental testing of GSA-derived combination therapies. Integrated pAkt response to heregulin-β stimulation in PE04 (left) and OVCAR4 (right) cell lines, treated with combinations of pertuzumab, LY294002 (LY) and UCN-01 (UCN). The data were normalised on the AUC of pAkt time-course in the absence of any drugs.
    Figure Legend Snippet: Experimental testing of GSA-derived combination therapies. Integrated pAkt response to heregulin-β stimulation in PE04 (left) and OVCAR4 (right) cell lines, treated with combinations of pertuzumab, LY294002 (LY) and UCN-01 (UCN). The data were normalised on the AUC of pAkt time-course in the absence of any drugs.

    Techniques Used: Derivative Assay



    Similar Products

    macrophagecolony stimulating factor  (MedChemExpress)
    94
    MedChemExpress macrophagecolony stimulating factor
    Macrophagecolony Stimulating Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/macrophagecolony stimulating factor/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    macrophagecolony stimulating factor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    stimulation by heregulin  (R&D Systems)
    94
    R&D Systems stimulation by heregulin
    Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to <t>heregulin-β</t> <t>stimulation</t> ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.
    Stimulation By Heregulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stimulation by heregulin/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    stimulation by heregulin - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to heregulin-β stimulation ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.

    Journal: European Journal of Pharmaceutical Sciences

    Article Title: Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network

    doi: 10.1016/j.ejps.2011.10.026

    Figure Lengend Snippet: Testing GSA predictions of drug targets in ErbB2/3 network. Experimental confirmation of drug targets, predicted by GSA, in PE04 (A and B) and OVCAR4 (C and D) cell lines: time course profile (left) and integrated pAkt response (right) to heregulin-β stimulation ± pertuzumab (Per), LY294002 (LY) and UCN-01 (UCN). All integrals were normalised on the value of S pAkt observed in the absence of any inhibitors. The error-bars indicate 95% confidence intervals of technical replicates.

    Article Snippet: Cells were treated with UCN-01 (protein kinase inhibitor; Calbiochem #539644; final concentration of 1 μM), LY294002 (PI3 kinase inhibitor; Calbiochem #440204; final concentration 20 μM), Pertuzumab (ErbB2 inhibitor; final concentration 100 nM) and stimulation by Heregulin (R&D Systems; 396-HB-CF) was at final concentration of 1 nM.

    Techniques:

    Experimental testing of GSA-derived combination therapies. Integrated pAkt response to heregulin-β stimulation in PE04 (left) and OVCAR4 (right) cell lines, treated with combinations of pertuzumab, LY294002 (LY) and UCN-01 (UCN). The data were normalised on the AUC of pAkt time-course in the absence of any drugs.

    Journal: European Journal of Pharmaceutical Sciences

    Article Title: Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network

    doi: 10.1016/j.ejps.2011.10.026

    Figure Lengend Snippet: Experimental testing of GSA-derived combination therapies. Integrated pAkt response to heregulin-β stimulation in PE04 (left) and OVCAR4 (right) cell lines, treated with combinations of pertuzumab, LY294002 (LY) and UCN-01 (UCN). The data were normalised on the AUC of pAkt time-course in the absence of any drugs.

    Article Snippet: Cells were treated with UCN-01 (protein kinase inhibitor; Calbiochem #539644; final concentration of 1 μM), LY294002 (PI3 kinase inhibitor; Calbiochem #440204; final concentration 20 μM), Pertuzumab (ErbB2 inhibitor; final concentration 100 nM) and stimulation by Heregulin (R&D Systems; 396-HB-CF) was at final concentration of 1 nM.

    Techniques: Derivative Assay